• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Mayo Clinic, SandboxAQ Expand Collaboration to Advance AI Cardiac Diagnostics in Amyloidosis

by Fred Pennic 01/17/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Image by freepik

What You Should Know:

– Mayo Clinic is expanding its collaboration with SandboxAQ, a provider of artificial intelligence (AI) medical apps to explore the use of electrocardiography (ECG) and magnetocardiography (MCG) technologies for characterizing disease progression and treatment response in patients with amyloidosis.

– The expanded partnership highlights the potential of combining AI and advanced sensing technology to revolutionize cardiac diagnostics.

Improved Detection and Monitoring of Amyloidosis and Other Cardiac Conditions

Amyloidosis is a condition characterized by the buildup of abnormal protein deposits in organs and tissues, including the heart. Early diagnosis and accurate monitoring are crucial for effective management, but current tools often fall short in detecting subtle changes in cardiac function.

The expanded collaboration aims to address this challenge by integrating the established reliability of ECG with the cutting-edge sensitivity of MCG. MCG is a non-invasive technology that measures the magnetic fields generated by the heart’s electrical activity, providing a more detailed picture of cardiac function compared to ECG alone.

By combining these two modalities with SandboxAQ’s advanced AI algorithms, the partnership seeks to develop a novel diagnostic solution that offers deeper insights into the electrical and magnetic activity of the heart. This approach has the potential to:

  • Improve early detection of amyloidosis: Identify subtle changes in cardiac function that may be missed by traditional methods.
  • Enhance disease monitoring: Track disease progression and treatment response more accurately over time.
  • Enable personalized treatment: Guide clinical decision-making and optimize treatment strategies for individual patients.

“By uniting AQMed’s technical innovation with Mayo Clinic’s renowned research and clinical excellence, we aim to make a meaningful impact on the lives of amyloidosis patients across the globe in the near future,” said Kit Yee Au-Yeung, GM of SandboxAQ’s AQMed division.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cardiac Monitoring, heart disease

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

2026 Predictions & Trends

Healthcare 2026 Forecast: Executives on AI Survival, Financial Reckoning, and the End of Point Solutions

2026 Healthcare Executive Predictions: Why the AI “Pilot Era” Is Officially Over

Most-Read

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

NYC Health + Hospitals to Acquire Maimonides in $2.2B Safety Net Overhaul

KLAS Report: Why Hospitals Are Choosing Efficiency Over 'Agentic' AI Hype in 2025

KLAS Report: Why Hospitals Are Choosing Efficiency Over ‘Agentic’ AI Hype in 2025

Advanced Primary Care 2026: Top 6 Investments for Health Systems According to Harvard Medical School

Advanced Primary Care 2026: Top 6 Investments for Health Systems According to Harvard Medical School

AI Nutrition Labels: The Key to Provider Adoption and Patient Trust?

AI Nutrition Labels: The Key to Provider Adoption and Patient Trust?

Kristen Hartsell, VP of Clinical Services, RedSail Technologies

The Pharmacy Closures Crisis: How Independent Pharmacies Are Fixing Pharmacy Deserts

HHS Launches 'OneHHS' AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

HHS Launches ‘OneHHS’ AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |